CVRx, Inc.

What they do

CVRx develops, manufactures and commercializes Barostim, an implantable pulse generator and stimulation lead that delivers electrical pulses to baroreceptors in the carotid artery to modulate the autonomic nervous system in HFrEF patients. The device is indicated for NYHA Class III or II patients (with recent Class III history) on guideline-directed medical therapy with LVEF of 35% or less and NT-proBNP under 1,600 pg/mL, and is CE Marked for HFrEF and resistant hypertension. Manufacturing, including final assembly, testing and packaging of the IPG and lead, is handled at the company's Minneapolis headquarters using third-party component suppliers. Sales are directed at electrophysiologists, heart failure specialists, cardiologists and vascular surgeons, but hospitals are the purchasing customers in the U.S.

Revenue drivers

• U.S. Barostim sales — Q2 2026 U.S. revenue was $14.8 million, up 21% year over year, on 466 revenue units, powered by 258 active implanting centers and 56 U.S. sales territories.
• Europe Barostim sales — Q2 2026 Europe revenue was $0.9 million, down 31% year over year, on 40 revenue units versus 61 a year earlier, with the territory count flat at five.
• Medicare reimbursement pathway — About 67% of the target U.S. patient population is Medicare-eligible; CMS's final 2026 Physician Fee Schedule established Category I CPT codes and national pricing for Barostim implant and follow-up, and all MACs have retired automatic coverage denial policies.

Recent performance

Total Q2 2026 revenue was $15.7 million, up 16% from the prior-year quarter, with U.S. revenue of $14.8 million up 21% and Europe revenue of $0.9 million down 31%. Gross margin improved to 87% from 84%, while net loss was $14.0 million, or $0.53 per share, versus a $14.7 million loss a year earlier. R&D rose 27% to $3.1 million and SG&A rose 1% to $23.6 million, with the SG&A increase driven mainly by stock-based compensation and legal expenses. Revenue was $56.7 million for full-year 2025 with a net loss of $53.3 million, and the company has reported negative operating cash flow every year from 2021 through 2025.

Strategy

CVRx states it will continue expanding and training its U.S. sales force and investing in U.S. commercial infrastructure, while building an in-house market access team to obtain prior authorizations for Barostim case by case. It is pursuing broader payer coverage, including commercial payers, alongside its Medicare focus, and is running the BENEFIT-HF trial as part of its clinical and reimbursement strategy. The company amended its Innovatus Capital Partners loan agreement in January 2026 to increase available term loans to $100.0 million and extend maturity to 2031, borrowing an additional $10.0 million at closing. Management has said it expects to keep incurring net losses for the next several years and may require additional equity or debt funding.

Risks

• Single-product dependence — The business is highly dependent on Barostim, and failure to increase market acceptance of that one product would directly impair revenue.
• Persistent losses and cash use — Net losses were $53.3 million in 2025 and $60.0 million in 2024, with accumulated deficit of $590.7 million at December 31, 2025 and operating cash flow of negative $40.2 million in 2025.
• Payer coverage friction — Management cited a prolonged challenge with one of its largest payers and lower sales force productivity in cutting its 2026 outlook, and coverage generally remains claim-by-claim where positive policies do not exist.
• Supply chain concentration — Barostim uses components from a limited number of third-party suppliers, some with significant lead times, prompting the company to hold higher inventory to guard against interruptions.

Outlook

Management reduced its outlook for the balance of 2026, citing fewer sales territories than anticipated, lower sales force productivity and a prolonged challenge with one of its largest payers. The CEO said the company is taking direct action on these headwinds while keeping confidence in long-term fundamentals, supported by growth in its most stable regions and early progress on the BENEFIT-HF trial. CVRx also flagged Humana's Medicare Advantage coverage policy effective May 1, 2026, its first coverage policy of that kind, as reimbursement progress. The company continues to expect net losses for the next several years and possible additional financing.